AH Europe 2020 | Kisaco Research

2020 KEYNOTES FROM WORLD RENOWNED DIGITAL AND TECH EXPERTS ANNOUNCED

Shaping the Future of Animal Health

Watch the Highlights
London, UK
24-26 February, 2020

Get ahead of the game and apply for the Innovation Showcase! You can already apply, free of charge, via our form below. All applicants are eligible for a discounted ticket to come and meet the investors face-to-face at the 2020 meeting.

2020 keynote speakers revealed

Three world renowned digital and technology experts from external industries will be giving keynote presentations at Animal Health Investment Europe 2020. This is a great opportunity for animal health and nutrition companies to learn from and adapt to the impacts of disruptive technologies in other sectors in a way that will drive transformative change and open new opportunities for their businesses. 

Read the full speaker biographies and find out more in our keynote announcement - 

Download 2020 Keynote Speaker Announcement 

Why Attend?

Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutritional health, and connecting those businesses with financial investors and strategic corporate partners from 38 countries worldwide.

To complement our investment pitches, we host CEO-level discussions that address the trends and market dynamics of the animal health industry, across all species.

Networking is a large part of what we offer - across the two days you can meet face-to-face with decision makers from the full spectrum of the animal pharma and nutritional health industry: from our 200 start-ups (such as Proteon Pharma and REX Animal Health, the winners of the 2019 Innovation Showcase), to C-Suite leaders from 18 of the top 20 animal health companies (including Clint Lewis of Zoetis, Joachim Hasenmaier and Jeff Simmons of Elanco).

Book now to come and see for yourself!

Animal Health Innovation, Innovative Solutions in...

500+
Attendees
1500+
1-to-1 Meetings
200+
Start-ups
24
Emerging Companies Presenting
25+
Private Meetings per person

Speakers

 

Kristin Peck

Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
Zoetis

Kristin Peck is executive vice president and group president of U.S. Operations, Business Development and Strategy at Zoetis, the world leader in animal health, and was recently named CEO-elect by the company and a member of the Board of Directors. Peck will assume the role of CEO on January 1, 2020.

Kristin Peck

Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
Zoetis

Kristin Peck

Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
Zoetis

Kristin Peck is executive vice president and group president of U.S. Operations, Business Development and Strategy at Zoetis, the world leader in animal health, and was recently named CEO-elect by the company and a member of the Board of Directors. Peck will assume the role of CEO on January 1, 2020.

In her current role, she manages the livestock and companion animal businesses in the United States, overseeing the company's largest market with nearly $2.9 billion in revenue. Under her leadership in the last three years, the U.S. business has generated more than 20% revenue growth. Ms. Peck also leads the company’s corporate strategy and business development functions worldwide. 

Ms. Peck helped usher Zoetis through its IPO in 2013 and has been a driving force of change in many roles at the company including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. 

Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. In this role, she led Pfizer's merger and acquisition, licensing, venture capital, alliance management and innovative business model activities. She was also responsible for the evaluation of strategic alternatives for Pfizer's Animal Health and Nutrition businesses – paving the way for a public animal health company and attractive investment opportunity. 

Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan. 

Ms. Peck is a member of the Thomson Reuters' Board of Directors and serves on the Human Resources and Governance Committees. In addition, she is a member of the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School.  As a recipient of the 2019 Feather in Her Cap Award, she has been recognized for her leadership and contributions to the animal health industry, and her work in mentoring women and helping them advance their careers in animal health.  

Ms. Peck holds a bachelor's degree from Georgetown University and a Master of Business Administration from Columbia Business School.

 

 

Mike Ellis

Senior Vice President and President of Europe
Covetrus

Michael Ellis is the senior vice president and president of Europe at Covetrus. He has held previous positions as CFO, general manager, vice president, and president of Europe at Henry Schein Animal Health at Henry Schein. Michael is a Fellow Chartered Management Accountant, FCMA, and has a diploma in business studies from Sheffield University.

Mike Ellis

Senior Vice President and President of Europe
Covetrus

Mike Ellis

Senior Vice President and President of Europe
Covetrus

Michael Ellis is the senior vice president and president of Europe at Covetrus. He has held previous positions as CFO, general manager, vice president, and president of Europe at Henry Schein Animal Health at Henry Schein. Michael is a Fellow Chartered Management Accountant, FCMA, and has a diploma in business studies from Sheffield University.

 

Laurie Hueneke

Executive Director, Animal Health Public Policy & Government Relations
MSD Animal Health

Laurie Hueneke

Executive Director, Animal Health Public Policy & Government Relations
MSD Animal Health

Laurie Hueneke

Executive Director, Animal Health Public Policy & Government Relations
MSD Animal Health
 

Dave Williams

Vice President & CIO
MSD Animal Health

Dave Williams

Vice President & CIO
MSD Animal Health

Dave Williams

Vice President & CIO
MSD Animal Health
 

Joachim Hasenmaier

Independent Animal Health Expert

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

Joachim Hasenmaier

Independent Animal Health Expert

Joachim Hasenmaier

Independent Animal Health Expert

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.

In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.

 

Kathy V. Turner

Corporate Vice President, EMEA & Asia Pacific
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms.

Kathy V. Turner

Corporate Vice President, EMEA & Asia Pacific
IDEXX

Kathy V. Turner

Corporate Vice President, EMEA & Asia Pacific
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

 

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines.

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

 

Mark Heffernan

CEO
Stonehaven Incubate

Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.

Mark Heffernan

CEO
Stonehaven Incubate

Mark Heffernan

CEO
Stonehaven Incubate

Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.

Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.

 

Maarten Goossens

Co-founder and Principal
Anterra Capital

Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management. 

Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture. 

Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.

Maarten Goossens

Co-founder and Principal
Anterra Capital

Maarten Goossens

Co-founder and Principal
Anterra Capital

Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management. 

Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture. 

Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.

 

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.

With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.

With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.

For three years, Simon was the Animal Sciences & Aquaculture specialist for the Department for International Trade. Last year, he was appointed a GlobalScot in the animal health & aquaculture sector by the Office of the First Minister in Scotland.

Simon is a past president of the North of Ireland Veterinary Association and of the Northern Ireland Branch of BVA. He currently chairs the UK One Health Coordination Group and is one of two BVA representatives at the Federation of Veterinarians in Europe (FVE). He also chairs the FVE FishMedPlus Coalition.

A STEM Ambassador, he is also actively involved in the provision of veterinary careers advice, regularly mentoring applicants to veterinary school. He is also an ambassador for the livestock development charity, Send a Cow, and a trustee of the Animal Welfare Foundation.

Follow Simon on Twitter:
@simondocvet   @britishvets
#OneVeterinaryCommunity   #AStrongVoiceForVets

 

David Prien

CEO
FirstVet

David founded FirstVet in 2016 and has previously run several pet-related startups in the Nordics, taking them from early stages to exits. Graduated from SSE with a double degree in Business & Retail Management.

David Prien

CEO
FirstVet

David Prien

CEO
FirstVet

David founded FirstVet in 2016 and has previously run several pet-related startups in the Nordics, taking them from early stages to exits. Graduated from SSE with a double degree in Business & Retail Management.

 

Björgólfur Hávardsson

R&D Director
Seafood Innovation Cluster

Björgólfur Hávardsson MSc, is the Innovation Manager with the Seafood Innovation Cluster, a Norwegian Centre of Expertise member based out of Bergen, Norway.

Björgólfur Hávardsson

R&D Director
Seafood Innovation Cluster

Björgólfur Hávardsson

R&D Director
Seafood Innovation Cluster

Björgólfur Hávardsson MSc, is the Innovation Manager with the Seafood Innovation Cluster, a Norwegian Centre of Expertise member based out of Bergen, Norway.

After three decades of multiple biological roles in the aquaculture industry, Mr. Hávardsson has an extensive knowledge of the biological possibilities and challenges in modern salmon farming. Through working in the industry on such diverse fields as fish counting, biomass estimation, smoltification, fish welfare, feeding systems and -behaviour as well as writing practical books on netfouling in Europe and South America, Hávarðsson is experienced in developing and presenting ideas and practical methods through courses, presentations and articles in several languages.

Mr. Hávardsson holds a Master´s degree in Aquaculture Biology from the University of Bergen (UIB) and a degree from an executive program in Strategy and Branding in the seafood industry from the Norwegian School of Economics (NHH).

 

Alexis Nahama

SVP Corporate Development, Sorrento Therapeutics and President, ARK Animal Health

Alexis Nahama

SVP Corporate Development, Sorrento Therapeutics and President, ARK Animal Health

Alexis Nahama

SVP Corporate Development, Sorrento Therapeutics and President, ARK Animal Health
 

Linda Dixon

Group Leader, African Swine Fever Virus
The Pirbright Institute

Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.

Linda Dixon

Group Leader, African Swine Fever Virus
The Pirbright Institute

Linda Dixon

Group Leader, African Swine Fever Virus
The Pirbright Institute

Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.

Linda’s group has focussed on research underpinning the development of effective vaccines. Their approach has been to determine genome sequences of virulent and attenuated (weakened) isolates to help define the molecular determinants of virulence and identify those genes involved in evading host defences. The group has characterised ASFV proteins that inhibit host pathways involved in activating the host’s defences. These include proteins that inhibit host gene expression (transcription) responses, signal molecule induction and stress-activated responses. This knowledge has been applied to the rational development of candidate live attenuated ASFV vaccines by targeted gene deletions. 

In collaboration with the Vaccinology Group they have compared host responses in vitro (in glass) and in vivo (in animal) and induction of protective immune responses in pigs immunised with these gene manipulated and natural attenuated ASFV strains. The group has also collaborated with these groups and The Jenner Institute to screen ASFV antigens for those important in induction of protective immunity, in particular those which induce strong immune (CD8+ T cell) responses. This information will be applied to development of candidate virus-vectored vaccines.

In addition Linda provides advice on ASFV nationally to Defra and internationally as an OIE expert and is Chair of the Asfarviridae Study Group of the International Committee on Taxonomy of Viruses and a Jenner Institute Investigator. 

 

Justin Sherrard

Global Strategist - Animal Protein
Rabobank

As Global Strategist Animal Protein, Justin Sherrard is responsible for the timely and agenda-setting analysis of issues of strategic importance to animal protein companies around the world.

In his research and client engagement, Justin focusses on business opportunities in animal protein through, for example, increased production efficiencies, better access to growth markets and stronger supply chain models.

Justin Sherrard

Global Strategist - Animal Protein
Rabobank

Justin Sherrard

Global Strategist - Animal Protein
Rabobank

As Global Strategist Animal Protein, Justin Sherrard is responsible for the timely and agenda-setting analysis of issues of strategic importance to animal protein companies around the world.

In his research and client engagement, Justin focusses on business opportunities in animal protein through, for example, increased production efficiencies, better access to growth markets and stronger supply chain models.

Prior to his current role, Justin has worked at RaboResearch Food & Agribusiness as Global Manager Research, Global Strategist F&A Supply Chains, and General Manager of Food & Agribusiness Research for Rabobank in Australia and New Zealand. He joined Rabobank in 2009.

Justin has also worked as an independent advisor to leading blue chip companies, not-for-profit organisations and governments, applying his knowledge of food & agribusiness, energy and natural resources issues, including sustainability and climate change.

Justin has over 20 years of global experience having worked in Europe, the United States, Latin America, New Zealand as well as his native Australia. He holds a Master of Applied Science and Bachelor of Science from the University of New South Wales in Sydney, Australia.

 

 

Jean-Luc Michel

Senior Vice President, Companion Animal Strategic Business Unit
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

Jean-Luc Michel

Senior Vice President, Companion Animal Strategic Business Unit
Boehringer Ingelheim

Jean-Luc Michel

Senior Vice President, Companion Animal Strategic Business Unit
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

 

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.

With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty

Senior Vice President
British Veterinary Association

Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.

With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.

For three years, Simon was the Animal Sciences & Aquaculture specialist for the Department for International Trade. Last year, he was appointed a GlobalScot in the animal health & aquaculture sector by the Office of the First Minister in Scotland.

Simon is a past president of the North of Ireland Veterinary Association and of the Northern Ireland Branch of BVA. He currently chairs the UK One Health Coordination Group and is one of two BVA representatives at the Federation of Veterinarians in Europe (FVE). He also chairs the FVE FishMedPlus Coalition.

A STEM Ambassador, he is also actively involved in the provision of veterinary careers advice, regularly mentoring applicants to veterinary school. He is also an ambassador for the livestock development charity, Send a Cow, and a trustee of the Animal Welfare Foundation.

Follow Simon on Twitter:
@simondocvet   @britishvets
#OneVeterinaryCommunity   #AStrongVoiceForVets

 

Jo Malone

Chief Executive Officer
Vet Partners

Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

 

In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

 

Jo Malone

Chief Executive Officer
Vet Partners

Jo Malone

Chief Executive Officer
Vet Partners

Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

 

In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

 

In 2015 she became Managing Director of VetPartners and then CEO in 2016.

 

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd
 

Michael Balz

Partner
McKinsey & Company

Michael Balz

Partner
McKinsey & Company

Michael Balz

Partner
McKinsey & Company
 

Carel du Marchie Sarvaas

Secretary General
HealthforAnimals

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel du Marchie Sarvaas

Secretary General
HealthforAnimals

Carel du Marchie Sarvaas

Secretary General
HealthforAnimals

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins Universi

 

David Hallas

Managing Director
Sure Petcare and HomeAgain

David Hallas

Managing Director
Sure Petcare and HomeAgain

David Hallas

Managing Director
Sure Petcare and HomeAgain
 

Marc de Beer

Senior Vice President, US Food Animal and Global Nutritional Health
Elanco Animal Health

Marc de Beer

Senior Vice President, US Food Animal and Global Nutritional Health
Elanco Animal Health

Marc de Beer

Senior Vice President, US Food Animal and Global Nutritional Health
Elanco Animal Health
 

Dr. Silke Birlenbach

Pegasus Life Sciences Consulting

Dr. Silke Birlenbach

Pegasus Life Sciences Consulting

Dr. Silke Birlenbach

Pegasus Life Sciences Consulting
 

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors
Boehringer Ingelheim

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors
Boehringer Ingelheim

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors
Boehringer Ingelheim
 

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).

TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).

TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.

Michael also serves as Managing Partner of Covenant Animal Health Partners, a TechAccel subsidiary that focuses on development of “revenue-ready” animal health products for both companion and farm animals.

Before founding TechAccel, Michael served as the fifth President and Chief Executive Officer of MRIGlobal – one of the nation's most prominent research institutions. In his 14 years with MRIGlobal (formerly Midwest Research Institute), he led its growth from 2 to 17 national and international locations.

Michael has more than 30 years of experience working with the private sector and government agencies, including laboratory management positions at Applied Marine Research Laboratory in Norfolk, Va., and program management for the Harbor Branch Oceanographic Institution in Fort Pierce, Fla. He was President and Chairman of startup Brevard Teaching and Research Laboratories, a post he held until the company was acquired by MRIGlobal.

Michael received a Ph.D. in Chemical Toxicology/Oceanography from Old Dominion University and a B.S. in Biology from Allegheny College. He has been a panelist, keynote speaker, lecturer, reviewer to several journals, and is the author of numerous publications, articles, book chapters, and technical reports.

He has served on several boards, including Labconco Corp. Board of Directors and University of Missouri-Kansas City Board of Trustees, as well as numerous civic organizations. He is a contributing opinion writer for Forbes.com.

Michael lives in suburban Kansas City.

Email: [email protected]
LinkedIn www.linkedin.com/in/michaelhelmstetter/

 

Spencer Swayze

CFA, Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

CFA, Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

CFA, Managing Director
Paine Schwartz Partners, LLC
 

Todd B. Richter C.F.A

Senior Managing Director, Global Healthcare Investment Banking Group
Guggenheim Partners

Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays.

Todd B. Richter C.F.A

Senior Managing Director, Global Healthcare Investment Banking Group
Guggenheim Partners

Todd B. Richter C.F.A

Senior Managing Director, Global Healthcare Investment Banking Group
Guggenheim Partners

Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays. From 1999 to 2016 Todd Richter was a Senior Managing Director in the Global Healthcare Corporate & Investment Banking Group at Bank of America Merrill Lynch. From 1981 to 1999, Mr. Richter served as the head of the healthcare services analytical team for Morgan Stanley. Todd Richter earned a B.B.A. in Finance from the College of William & Mary in 1979 and an M.B.A. in Finance with Honors from Indiana University in 1981. Todd was recognized 16 times as a member of the Institutional Investor’s All-America Research Team. He was also listed many times among the Wall Street Journal’s “All-Star” analysts and on the Reuters research poll. Mr. Richter is currently a member of the Board of Directors (Vice Chairman) of Bideawee, one of the nation’s leading animal rescue organizations; a member of the Board of Directors at the Stratton Mountain School (SMS) in Stratton, Vermont, a member of the Board of Directors at Animal Lighthouse Rescue (ALR), and a member of the Dean’s Council for the Kelley School of Business at Indiana University.  Finally Mr. Richter is on the Board and faculty of the Columbia University Mailman School of Public Health teaching a course on healthcare consolidation to MPH and MHA candidates. 

 

Cindy Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Cindy Cole

Partner
Digitalis Ventures

Cindy Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

 

Julia Stephanus

Founder and President
Avviare

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

Julia Stephanus

Founder and President
Avviare

Julia Stephanus

Founder and President
Avviare

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

 

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco Animal Health

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco Animal Health

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco Animal Health

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Mark Heffernan

CEO
Stonehaven Incubate

Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.

Mark Heffernan

CEO
Stonehaven Incubate

Mark Heffernan

CEO
Stonehaven Incubate

Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.

Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.

 

Malcolm Thomas

CEO
Agile Sciences Inc

Malcolm Thomas

CEO
Agile Sciences Inc

Malcolm Thomas

CEO
Agile Sciences Inc
 

Dino Dedic

Global Healthcare Investment Banking
Barclays

Dino Dedic

Global Healthcare Investment Banking
Barclays

Dino Dedic

Global Healthcare Investment Banking
Barclays
 

Joost Matthijssen

Investment Director
Nutreco NuFrontiers

Joost Matthijssen

Investment Director
Nutreco NuFrontiers

Joost Matthijssen

Investment Director
Nutreco NuFrontiers
 

Jason Cleaversmith

Independent Aquaculture Expert

Jason Cleaversmith is now an Independent Aquaculture Expert. He joined the Scottish Aquaculture Innovation Centre (SAIC) in April 2015 with a mandate to help transform the relationship between Industry and Academia, whilst concurrently facilitating economic growth for the Aquaculture Sector.

Jason Cleaversmith

Independent Aquaculture Expert

Jason Cleaversmith

Independent Aquaculture Expert

Jason Cleaversmith is now an Independent Aquaculture Expert. He joined the Scottish Aquaculture Innovation Centre (SAIC) in April 2015 with a mandate to help transform the relationship between Industry and Academia, whilst concurrently facilitating economic growth for the Aquaculture Sector.

Prior to joining SAIC he was the Head of the Novartis Aqua Health presence on Prince Edward Island, Canada where he oversaw 4 facilities, 125 staff and both R&D and Manufacturing related activities. Before joining Novartis, Dr. Cleaversmith led the Bioscience portfolio on behalf of the Province of Prince Edward Island and was responsible for the growth and economic development of the cluster by way of both inward investment and existing company growth.

His career spans time in Blue Chip organizations through to frontline SME positions in roles such as Business Development Director and Head of Operations. In addition, he was a member of the Executive at the Scottish Association for Marine Science and ledfrom inception the development of their commercial subsidiary and technology / knowledge transfer activities, including the building and population of the European Centre for Marine Biotechnology. Subsequently he has worked within the marine biotechnology sector, focusing on natural product discovery for the nutri-, cosme- and pharmaceutical sectors.

He is a Fellow of the Royal Society of Biology, Chartered Manager and is a member of the Institute of Directors. Prior voluntary positions include chair of the board for the University of Prince Edward Islands technology transfer office (Synapse), Vice Chair of the PEI BioAlliance and participated on the steering committee for the biotechnology program at Holland College.

Jason is a graduate of Edinburgh University, Scotland, with a major in Geology followed by a PhD in Marine Geochemistry and has subsequently completed an Executive MBA with the University of Glasgow, where he gained a Distinction.

 

Mark Boddy

CEO
PawSquad

Mark Boddy

CEO
PawSquad

Mark Boddy

CEO
PawSquad
 

Bruce Whitelaw

FRSB, Genus Chair of Animal Biotechnology R(D)SVS, Deputy Director (Partnerships) The Roslin Institute, Chairman Edinburgh Genomics and Roslin Innovation Centre University of Edinburgh
R(D)SVS, The Roslin Institute, University of Edinburgh

Bruce Whitelaw

FRSB, Genus Chair of Animal Biotechnology R(D)SVS, Deputy Director (Partnerships) The Roslin Institute, Chairman Edinburgh Genomics and Roslin Innovation Centre University of Edinburgh
R(D)SVS, The Roslin Institute, University of Edinburgh

Bruce Whitelaw

FRSB, Genus Chair of Animal Biotechnology R(D)SVS, Deputy Director (Partnerships) The Roslin Institute, Chairman Edinburgh Genomics and Roslin Innovation Centre University of Edinburgh
R(D)SVS, The Roslin Institute, University of Edinburgh
 

Tim Starzl

President
BioPlx

Tim Starzl

President
BioPlx

Tim Starzl

President
BioPlx
 

Sébastien Lafon

Founder
Adapt1st LLC

Sébastien Lafon

Founder
Adapt1st LLC

Sébastien Lafon

Founder
Adapt1st LLC
 

Peter McCarthy

President, Global Animal Health Group
Henry Schein, Inc.

Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.

Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.

Peter McCarthy

President, Global Animal Health Group
Henry Schein, Inc.

Peter McCarthy

President, Global Animal Health Group
Henry Schein, Inc.

Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.

Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.

Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.

Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.

Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.

 

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Apply for the 2020 innovation Showcase

Applications for the innovation showcase have now closed. Finalists will be announced soon. Keep your eye on our website and social media accounts for updates. 

What's new for 2020?
This year, 20 emerging companies will win the chance to present with winners split into two separate showcases that will run across the show:

10 start-ups will present their innovations in the companion animal & pet care space.

10 start-ups will present their innovations in the production animal & animal agri-tech space.

Showcase applicants are eligible for a discounted ticket to come and meet the investors face-to-face at next year's meeting in February.

 

 

Congratulations to all 24 of the 2019 Finalists, and thank you to the 60+ companies that applied to the Showcase.

Please click the "Innovation Showcase Finalists" PDF below to learn more about the most exciting innovations in animal health and nutrition from 2019...

Series Highlights

Animal Health Investment Europe, highlights video 2019    

Photo Gallery

Photos from February 2019 are now available to download and share - view the full photo gallery here.

Advisory Board

Clinton Lewis

Executive Vice President, President, International Operations
ZOETIS

Joachim Hasenmaier

Independent Animal Health Expert

George Gunn

Founder and CEO
Stonehaven Consulting AG

Linda Rhodes

Independent Animal Health Expert

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Alan Mackay

Executive Partner and Founder
GHO Capital

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Kathy V. Turner

Corporate Vice President, EMEA & Asia Pacific
IDEXX

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Selection Committee

Charles Hoare

Head of European Healthcare M&A
Stifel

Matthias Hofer

Partner
Stonehaven Consulting Group

Julia Stephanus

Founder and President
Avviare

Maarten Goossens

Co-founder and Principal
Anterra Capital

Sarai Kemp

VP Business Development
Trendlines Agtech

Paul Dick

President
Paul Dick & Associates Ltd

Isaac Fraynd

Dealflow Manager
Aqua-Spark

Spencer Swayze

CFA, Managing Director
Paine Schwartz Partners, LLC

Cindy Cole

Partner
Digitalis Ventures

Stephen Murray

Head of Animal Health Ventures
MSD Animal Health

The Agenda

You can download our latest agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Download the 2020 Agenda

Partners

Animal Health Investment Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.

Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health Investment series.

Headline Partner

Associate Partners

Knowledge Partner

Senior Event Partners

Consulting Partner

Event Partners

Media Partners

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Press Partnerships

Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:

  • Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
  • Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
  • Provide one free press pass to attend
  • Distribute promotional materials at the conference

If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:

Sarah Rowlands
Marketing Manager
T: +44 (0)203 696 2920
E: sarah.rowlands[@]kisacoresearch.com

Venue

Etc.venues 133 Houndsditch, London, UK

Great news! With over 430 people at the event this February, Animal Health Investment Europe has outgrown its usual venue. For 2020 we will be moving to another great central London location near Liverpool Street station:

Etc.venues 133 Houndstitch
London
EC3A 7BX

The Tower Hotel, St Katherine’s Way, London E1W 1LD   (0.8 mile from etc Houndsditch)

Rate: £160.00 includes vat and English breakfast

To book: call + 44 (0) 207 523 5063 or

Email: [email protected]

Quote block ref: KISA230220FC

Book by: 26 January 2020

ACCOMMODATION

Clayton Hotel

10 Drum St, London E1 7AT (0.4 mile from etc Houndsditch)
Rate: £195.00 includes vat & breakfast

To book a room please email: [email protected]

When booking, quote reference KISACO-7280763
Please book by
26th January 2020

Visit website for more details.

 

The Tower Hotel

St Katherine’s Way, London E1W 1LD   (0.8 mile from etc Houndsditch)
Rate: £160.00 includes vat and English breakfast

To book a room please call + 44 (0) 207 523 5063
Or email: [email protected]

When booking, quote reference KISA230220FC
Please book by 26th January 2020

 Visit website for more details.

Holiday Inn Whitechapel

5 Cavell St, London E1 2BP (1.1 mile from etc Houndsditch)

23rd February - £110.00 inc vat & English breakfast
24th February - £150.00 inc vat & English breakfast
25th February - £189.00 inc vat & English breakfast

To book online click here and quote: GA1 Limited KISACO
Please book by 24th January 2020

Visit website for more details.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Saturday, November 16, 2019 to Friday, December 20, 2019
Emerging Pass
£899 + VAT
Early Bird (Standard rate £999)
Pre-revenue companies
Companies up to £4 Million in annual revenue
Owners of veterinary practices
Academics
Charities
Angel and Venture Capital Investors
Please note: Those offering consultancy or market intelligence services do not qualify for this rate
Tuesday, December 3, 2019 to Friday, December 20, 2019
Delegate Pass
£1,699 + VAT
Early Bird (Standard rate £1,899)
Health and Nutrition companies (under £100m in annual revenue)
Digital & Tech Companies
Biotech Companies
Sunday, October 20, 2019 to Friday, December 20, 2019
Service Provider Pass
£2,399 + VAT
Early Bird (Standard Rate £2,699)
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Vet Service Companies
To increase your brand presence, contact Stephen: [email protected]
Saturday, November 16, 2019 to Friday, December 20, 2019
Multinational Pass
£2,399 + VAT
Early Bird (Standard Rate £2,699)
Companies over £100 Million in annual revenue
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a £49 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.